Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 637059, 7 pages
http://dx.doi.org/10.1155/2014/637059
Clinical Study

Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation

1Department of Hematology and Oncology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
2Department of Hematology and Oncology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany
3Department of Internal Medicine, Klinikum Merseburg, Weiße Mauer 52, 06217 Merseburg, Germany
4Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
5Division of Pediatric Hematology/Oncology, Department of Pediatrics, Technische Universität München, Kölner Platz 1, 80804 München, Germany

Received 9 March 2014; Accepted 21 May 2014; Published 15 June 2014

Academic Editor: Carlo Visco

Copyright © 2014 Mark Reinwald et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Pfeifer, B. Wassmann, W.-K. Hofmann et al., “Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate,” Clinical Cancer Research, vol. 9, no. 13, pp. 4674–4681, 2003. View at Google Scholar · View at Scopus
  2. K. E. Sanders, C. S. Ha, J. E. Cortes-Franco, C. A. Koller, H. M. Kantarjian, and J. D. Cox, “The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia,” Cancer, vol. 100, no. 10, pp. 2176–2180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. T. O'Hare, D. K. Walters, E. P. Stoffregen et al., “In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants,” Cancer Research, vol. 65, no. 11, pp. 4500–4505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Gabert, E. Beillard, V. H. J. van der Velden et al., “Standardization and quality control studies of “real time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer Program,” Leukemia, vol. 17, no. 12, pp. 2318–2357, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Thiede, M. Bornhäuser, U. Oelschlägel et al., “Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers,” Leukemia, vol. 15, no. 2, pp. 293–302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Pursche, O. G. Ottmann, G. Ehninger, and E. Schleyer, “High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 852, no. 1-2, pp. 208–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Porkka, P. Koskenvesa, T. Lundán et al., “Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia,” Blood, vol. 112, no. 4, pp. 1005–1012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Takayama, N. Sato, S. G. O'Brien, Y. Ikeda, and S.-I. Okamoto, “Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid,” British Journal of Haematology, vol. 119, no. 1, pp. 106–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Togashi, K. Masago, S. Masuda et al., “Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 70, no. 3, pp. 399–405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. O. Reman, A. Pigneux, F. Huguet et al., “Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group,” Leukemia Research, vol. 32, no. 11, pp. 1741–1750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Yokota, S. Kimura, S. Masuda et al., “INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity,” Blood, vol. 109, no. 1, pp. 306–314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kantarjian, F. Giles, L. Wunderle et al., “Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL,” The New England Journal of Medicine, vol. 354, no. 24, pp. 2542–2551, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Wassmann, H. Pfeifer, M. Stadler et al., “Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL),” Blood, vol. 106, no. 2, pp. 458–463, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Merante, A. A. Colombo, S. Calatroni et al., “Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation,” Bone Marrow Transplantation, vol. 44, no. 4, pp. 263–264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Tiribelli, A. Sperotto, A. Candoni, E. Simeone, S. Buttignol, and R. Fanin, “Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib,” Leukemia Research, vol. 33, no. 1, pp. 174–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Jabbour, A. Hochhaus, J. Cortes, P. La Rosée, and H. M. Kantarjian, “Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history,” Leukemia, vol. 24, no. 1, pp. 6–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. J. Garg, H. Kantarjian, S. O'Brien et al., “The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up,” Blood, vol. 114, no. 20, pp. 4361–4368, 2009. View at Publisher · View at Google Scholar · View at Scopus